Dr. Maloney on Challenges With CAR T-Cell Therapy in ALL

David G. Maloney, MD, PhD
Published: Monday, Oct 09, 2017



David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of chimeric antigen receptor (CAR) T-cell therapy in acute lymphocytic leukemia (ALL).

On August 30, 2017, the FDA approved tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Challenges still exist, says Maloney, namely the age cutoff. Studies are now being done conducted in adults, and the toxicities that are being seen are manageable, Maloney adds.
 


David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of chimeric antigen receptor (CAR) T-cell therapy in acute lymphocytic leukemia (ALL).

On August 30, 2017, the FDA approved tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Challenges still exist, says Maloney, namely the age cutoff. Studies are now being done conducted in adults, and the toxicities that are being seen are manageable, Maloney adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x